Navigation Links
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Date:10/12/2008

y engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi, about to start phase I/II for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA administered systemically in a human clinical study.

In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Quark Pharmaceuticals, Inc.

Juliana Friedman

+972 89 30 5111

jfriedman@quarkpharma.com

The Ruth Group (investors / media)

Sara Ephraim / Janine McCargo

(646) 536-7004 / 7033


SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... fiduciary duties to shareholders or violated the federal securities ... disclosed: "On September 11, 2014, [PDL] was orally notified ... LLP ("EY"), that it was resigning effective September 11, ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5
... of Orange Park is hosting a car wash to raise money ... AM at the Hooters of Orange Park located at 1740 Wells ... from the car wash will go toward the Kelly Jo Dowd ... the country is raising money through various charitable efforts in the ...
... Reinforce March of Dimes Message: Start Taking a Vitamin ... Women who take folic acid supplements for at ... their risk of having a premature baby by half, ... journal, PLOS Medicine.The study links pre-conceptional folate supplementation of ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing ... National Manufacturing Day by opening its doors to the ... additive manufacturing labs will be offered between 10 a.m. ... Southern and Dobson campus (1833 W. Southern Ave, Mesa, ... , The AzAMI at MCC was established in the ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” ... article , “We know that you want to care for ... want to do as well.” , The article explains to ... their Family Physicians who practice obstetrics while pregnant, during delivery, ... To learn more about Community Health Center of Snohomish County ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The children ... the balanced and active play they need. An empty ... Center - Lakeview Campus was transformed into a kid-designed ... of 150+ volunteers from Branches (@BranchesFL), ESPN (@TeamESPN), Disney ... , KaBOOM! believes a playground is more than a ...
(Date:9/19/2014)... York, NY (PRWEB) September 20, 2014 ... moderate revenue growth for the Vision Insurance industry ... pace, to the detriment of industry margins. From ... noticeably increase. Industry operators provide coverage for routine ... discounted pricing for eyeglasses, contact lens and refractive ...
(Date:9/19/2014)... 19, 2014 Are you tired of ... problems with seasonal allergies or sinus congestion? Fortunately, an ... alternative. , She conceived of Nose Pal to ... runny nose in public. Since it prevents nasal drip ... sanitary conditions, particularly when cooking or working closely with ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... with Autism is the focus of the research of one ... Economic and Social Research Council (ESRC) and the Young Foundation. ... the causes of autism rather than understanding it as a ... over a period of three years Dr Elizabeth Pellicano, from ...
... Lady Laura Bush,today saluted the U.S. Department of ... Prevention Initiative, announced today at,the National Prevention Summit, ... weight for children., Mrs. Bush delivered the ... event that highlights new approaches to prevention,and health ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") said ... dividend of $0.475 per share, payable in cash,on December ... 2007. The,dividend is the fourth quarterly installment of the ... quarterly installment of the Company,s 2007 annual dividend,will be ...
... bizarre behaviors and sudden deaths , , TUESDAY, Nov. ... Drug Administration advisory panel recommended Tuesday that the prescription ... label to reflect reports of bizarre behaviors and deaths ... a 9-5 vote, said that drug maker Roche Holding ...
... SAN DIEGO, Nov. 27 Gen-Probe Incorporated,(Nasdaq: GPRO ... the NASDAQ,20th Investor Program in London on Thursday, December ... a.m. Eastern Time). The,presentation is scheduled to be webcast ... investor information section of Gen-Probe,s website at, http://www.gen-probe.com . ...
... Address Growing Healthcare Trends and the Tools Health Plans ... ... Portico Systems, the leader in,Provider Network Management solutions, will host a ... practices for,provider network management. The complimentary series starts Tuesday,December 4th, showcasing ...
Cached Medicine News:Health News:Autism focus of prize winning research 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4Health News:FDA Panel Backs Stronger Warning for Tamiflu 2Health News:FDA Panel Backs Stronger Warning for Tamiflu 3Health News:Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program 2Health News:Portico Systems Offers Webinar Series to Share Provider Network Management Best Practices 2
30 Degree Angle Shaft with 1.0mm 90 Degree Angle Tip; in stainless steel....
0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
Medicine Products: